Press Releases 2025 2024 2023 2022 2021 2020 2019 all March 27, 2024 Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer March 27, 2024 Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium March 25, 2024 Dyne Therapeutics Announces CEO Transition March 13, 2024 Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days March 5, 2024 Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights February 14, 2024 Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference February 1, 2024 Dyne Therapeutics to Present at February Investor Conferences January 11, 2024 Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares January 5, 2024 Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference January 4, 2024 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock January 3, 2024 Dyne Therapeutics Announces Proposed Public Offering of Common Stock January 3, 2024 Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases January 2, 2024 Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials November 7, 2023 Dyne Therapeutics to Present at November Investor Conferences October 30, 2023 Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones September 28, 2023 Dyne Therapeutics to Present at October Investor Conferences September 20, 2023 Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 September 5, 2023 Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference August 3, 2023 Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights June 1, 2023 Dyne Therapeutics to Present at Jefferies Healthcare Conference Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page » Displaying 21 - 40 of 113
